Denali Therapeutics
Open
$21.58
Prev. Close
$21.59
High
$21.66
Low
$21.49
Market Snapshot
$3.44B
-6.8
-2.58
507
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The company is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. The company is also pursuing opportunities in other disease areas including oncology.
Denali Therapeutics paused the LUMA trial while advancing the Phase 2a BEACON trial focused on genetically targeted therapies for Parkinson's disease.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The company is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. The company is also pursuing opportunities in other disease areas including oncology.
Recently from Cashu
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah, Enhancing Biotech Credibility
Denali Therapeutics Achieves FDA Accelerated Approval for Avlayah Denali Therapeutics Inc. reaches a notable milestone with the U.S. Food and Drug Administration's (FDA) recent accelerated approval fo…
Denali Therapeutics Advances Neurodegenerative Disease Research Amid Market Instability
Denali Therapeutics Focuses on Advancements in Neurodegenerative Disease Research Amid Market Volatility Denali Therapeutics, a biotechnology company specializing in therapies for neurodegenerative di…
Denali Therapeutics Advances Neurological Treatments Despite Market Volatility and Economic Uncertainties
Denali Therapeutics: Focus on Neurological Advancements Amid Market Volatility In the midst of recent stock market fluctuations, Denali Therapeutics remains committed to its mission to advance treatme…
Denali Therapeutics Faces Regulatory Hurdles Amid Evolving FDA Standards for Neurodegenerative Drugs
Navigating Regulatory Challenges: Denali Therapeutics in a Shifting FDA Landscape As Denali Therapeutics advances its drug development pipeline geared towards combating neurodegenerative diseases, the…